Table 2.

St PETER HIV data and sample collection.

		Study Time Point (in months)
Administered Assessment	Description	Baseline	Short Check Ins	1 Mo.	3 Mo.	6 Mo.	12 Mo.
Demographics [41,42]	Participant demographics and socio-economic status	X					X
30-day Alcohol Timeline Followback (TLFB) [43]	Estimates of participant's daily drinking over the past 30 days	X		X	X	X	X
Alcohol Use Disorders Identification Test (AUDIT) [44]	Identifies persons with hazardous alcohol use	X				X	X
DSM-5 Alcohol Use Disorder [45]	Diagnosis of alcohol use disorders, with classifications of mild, moderate, and severe	X					X
Short Inventory of Problems (SIP) for Alcohol Use [46,47]	Assessment of adverse consequences of alcohol use	X		X	X	X	X
Penn Alcohol Craving Scale [48]	Instrument for assessing alcohol craving. Measures frequency, intensity, and duration of thoughts about drinking, as well as ability to resist drinking	X		X	X	X	X
Readiness to Quit Alcohol [49]	Assesses readiness to quit drinking via a readiness to change ruler	X		X	X	X	X
30-day Cigarette Timeline Followback (TLFB) [50,51]	Estimates of participant's daily cigarette smoking over the past 30 days	X		X	X	X	X
Tobacco Use (Fagerström) [52,53]	A measure of nicotine dependence	X		X	X	X	X
Other Tobacco Use [54]	Assesses tobacco use other than cigarette use	X		X	X	X	X
Tobacco Craving (QSU) [[55], [56], [57]]	Instrument for assessing craving to smoke	X		X	X	X	X
Readiness to Quit Tobacco [58]	Assesses readiness to quit smoking via a readiness to change ruler	X		X	X	X	X
Smoking Quit Attempts	Assesses whether participant attempted to quit smoking in past 6 months	X				X	X
HIV Risk Categories [59]	Asks about participant's potential exposure to HIV	X
Depressive Symptoms (CES-D) [60,61]	A measure of depressive symptomology	X		X	X	X	X
Anxiety (GAD-7)62	A measure of severity of anxiety	X		X	X	X	X
Trauma	Questions about traumatic experiences	X					X
HIV Testing and HCV Diagnosis	Dates and locations of HIV/HCV testing and HIV/HCV treatment	X					X
ART Use and Adherence [63]	Questions on ART and 30-day adherence	X				X	X
Opportunistic Infections [64]	Assesses any history of candida or yeast infection of the esophagus, TB, pneumonia, or toxoplasmosis	X					X
Co-Morbidities [65]	Participant and family medical history	X					X
Brief Chronic Pain Questionnaire [66,67]	Two questions about severity of body pain in the past week and duration of bodily pain	X				X	X
HIV Symptom Index [68]	A 20-item HIV symptom index includes patient-reported symptoms	X					X
Smoking-related symptoms [[69], [70], [71]]	Assesses smoking-related respiratory symptom severity	X		X	X	X	X
Reproductive Health	Questions regarding reproductive health	X					X
Falls [72]	Questions about falls in the past 6 months	X					X
TB testing and treatment	Questions about TB testing, diagnosis, and treatment	X					X
Healthcare Utilization [73]	How often participants see a physician and if they receive treatment for HIV and addiction	X				X	X
Medications	Prescription and non-prescription medication taken in the past 7 days	X		X	X	X	X
Brief Pain Inventory- SF [74]	Participant pain severity in the past 7 days	X				X	X
Drug Use (modified RBS) & Overdose [[75], [76], [77]]	Participant's self-reported drug use, modified to adapt to drug practices in Russia, and questions regarding history of overdose	X		X	X	X	X
24 Hour Activities	Participant past 24-h activities that may impact inflammatory biomarkers measured	X		X	X	X	X
Social Support Scale [78,79]	Measures access to companionship, assistance, or other types of support	X					X
Veterans Rand 12-Item Health Survey plus 4 cognitive questions from MOS-HIV [80,81]	Assessment of overall health and cognitive function	X					X
Smartphones	Asks whether participant owns a smartphone and whether they would be willing to use a free app to help quit drinking or smoking						X
Medication Adherence [63]	Adherence to study medication in the past week, as indicated by measurement on a ruler ranging from 0 to 100 and additional questions on adherence patterns		X	X	X
Medication Satisfaction [82]	Participant satisfaction with study medication			X	X
Blinding Questions	Questions on which study medication the participant believes to be taking			X	X
Clinical and Laboratory Values/Testing		Baseline	Short Check Ins	1 Mo.	3 Mo.	6 Mo.	12 Mo.
Height (m/cm)		X		X	X	X	X
Weight (kg)		X		X	X	X	X
Breath Alcohol Content (%)		X		X	X	X	X
Exhaled Carbon Monoxide (abstinence threshold < 10 ppm)_		X		X	X	X	X
Urine Pregnancy Testing		X		X	X
Blood Pressure (mmHG)		X		X	X	X	X
Urine Nicotine Metabolite Testing		X			X
Reynolds Risk Score (Cholesterol [total and HD], hsCRP)		X			X
VACS Index (HIV Viral Load, CD4 count, AST/ALT, Creatinine, Hemoglobin & Platelets, HCV Aba)		X			X
Nicotine Metabolite Ratio (NMR) (Whole blood)		X
Available Repository Samples		Baseline	Short Check Ins	1 Mo.	3 Mo.	6 Mo.	12 Mo.
DBS Cards (PEth)		X		X	X
Serum and Plasma		X		X	X	X	X

^aHCV Ab will be measured at baseline, and if negative at baseline, again at 3 months.